Glenmark's interim data from PMS Study on Favipiravir released
The study was conducted in patients with mild to moderate COVID-19
The study was conducted in patients with mild to moderate COVID-19
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Subscribe To Our Newsletter & Stay Updated